Goldman Sachs Maintains Neutral on GoodRx Holdings, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Eric Sheridan has maintained a Neutral rating on GoodRx Holdings (NASDAQ:GDRX) but has lowered the price target from $7 to $6.
November 10, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs maintains a Neutral rating on GoodRx Holdings and reduces the price target from $7 to $6.
The reduction in price target by a major analyst like Goldman Sachs suggests a less optimistic outlook on the company's stock price, which could lead to a negative short term impact on the stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100